Multi-parametric MRI for Therapeutic Response Prediction in Rectal Cancer
Ontology highlight
ABSTRACT: Interventions: Single arm prospective observationaI imaging biomarker study.
Patients will have standard treatment, consisting of neoadjuvant chemoradiotherapy followed by surgery. There will be no change to the patient’s treatment by participating in this study. Patients participating in this study will have multi-parametric MRI and PET/CT at the following 3 time-points:
1. Prior to chemoradiotherapy
2. During the third week of chemoradiotherapy
3. Post chemoradiotherapy, within 1 week prior to surgery.
A multi-parametric MRI incorporates standard morphological as well as diffusion weighted imaging and dynamic contrast enhanced sequences.
The total follow-up duration will be 2 years from date of surgery.
Primary outcome(s): Correlation of multi-parametric MRI (diffusion weighted imaging (DWI) and dynamic contrast enhanced (DCE)) at 3 Tesla with surgical histopathology tumour regression grade (TRG).
Histopathological assessment will be performed on surgical specimens. TRG assessment will be performed as per the modified classification of Ryan et al set out in the AJCC Cancer Staging Manual, 7th Edition as follows:
TRG 0 (complete response) - no viable cancer cells
TRG 1 (moderate response) - single cells or small groups of cancer cells
TRG 2 (minimal response) - residual cancer outgrown by fibrosis
TRG 3 (poor response) - minimal or no tumour kill; extensive residual cancer.
[At baseline pre-chemoradiotherapy, week 3 of chemoradiotherapy, and post-chemoradiotherapy (within 1 week prior to surgery) ]
DISEASE(S): Cancer-bowel-back Passage (rectum) Or Large Bowel (colon),Rectal Cancer
PROVIDER: 2464730 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA